Skip to main content

Table 1 Characteristics at baseline registration of PLWH enroled by Site

From: Accuracy of the tuberculosis point-of-care Alere determine lipoarabinomannan antigen diagnostic test using α-mannosidase treated and untreated urine in a cohort of people living with HIV in Guatemala

Variable

  

Sitea1, n = 266

 

Sitea 2, n = 95

p valueb

nc

%d

nc

%d

 

Age

Median (IQR)

264

36 (28–51)

95

36 (31–44)

0.831

Sex

 

266

 

95

 

0.229

 

Male

 

71.54

 

77.89

 
 

Female

 

28.46

 

22.11

 

Diabetese

 

245

 

32

 

< 0.001

 

Yes

 

3.27

 

50.00

 
 

No

 

96.73

 

50.00

 

BMIf

 

217

 

95

 

0.146

   

19.71 (17.34–22.40)

 

18.82 (16.60–21.50)

 

TB symptoms

      

 Cough

 

264

 

71

 

0.639

 

Yes

 

72.24

 

74.74

 

 Weight lost

 

265

 

91

 

NA

 

Yes

 

48.11

 

100

 

 Night sweating

 

264

 

95

 

0.002

 

Yes

 

48.11

 

66.32

 

 Fever

 

263

 

79

 

NA

 

Yes

 

39.54

 

100

 

 CD4 values at baseline

 

247

 

95

 

< 0.001

   

185.50 (89–398)

 

49 (19–121)

 

 Viral load (copies/ml)

 

241

 

95

 

0.059

   

39 200 (861–173 000)

 

93 616 (6044–242 469)

 

 cART regimeng

 

226

 

95

 

< 0.001

 

1st line

 

89.38

 

34.74

 
 

2nd line

 

10.62

 

65.26

 

 cART defaulters

      
 

Yes

 

18.72

 

18.00

0.431

 Death

 

260

 

95

  
 

Yes

 

11.20

 

27.37

< 0.001

  1. NA Not applied
  2. aSite = Site 1 includes UAI 1 = “Dr. Isaac Cohen Alcahé” UAI and Rodolfo Robles Hospital. Site 2 includes UAI 2 = “Dr. Carlos Rodolfo Mejía-Villatoro” UAI and Roosevelt Hospital
  3. bPearson’s Chi squared p values for categorical variables and Mann-Whitney median comparison p value for independent samples
  4. cVariable sample size
  5. dData are number (%) or median (IQR)
  6. eHba1c measurements in % above 6.15 were considered the threshold for diabetic patients
  7. fIn kg/m2
  8. g1st line regimens are based on a-ABC in combination with 3TC and either EFV or NVP or LPV/RTV, or ABC in combination with AZT and either EFV or LPV/RTV, or ABC in combination with TDF and EFV; b-AZT in combination with 3TC and either EFV, or NVP, or LPV/RTV or ABC; c-TDF in combination with FTC and either 3TC, or EFV, or NVP, or LPV/RTV, or AZT and 3TC
  9. 2nd line regimens are based on: a-ABC in combination with AZT and LPV/RTV, or in combination with DDI plus EFV, or DDI plus NVP or DDI plus SQV/RTV, b-AZT in combination with 3TC plus ATV, or ATV/RTV or ATV/SQV, or AZT in combination with DDI plus LPV/RTV, c-DDI in combination TDF and EFV, or DDI in combination with 3TC plus NVP, or EFV, or SQV/RTV, or LPV/RTV
  10. 3rd line regimens and regimens including RAL, DRV, MRV used due to genetic resistance are included in 2nd line regimens. AZT (azidovudine), FTC (emtricitabine), TDF (tenofovir), NVP (nevirapine), ABC (abacabir), 3TC (lamivudine), LPV/RTV (lopinavir/ritonavir), EFV (efavirenz), ATV (atazanavir), RAL (raltegravir), DRV (darunavir), MRV (maraviroc), DDI (didanosine)
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us